Eintrag weiter verarbeiten
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion
Gespeichert in:
| Zeitschriftentitel: | Acta Ophthalmologica |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Acta Ophthalmologica, 93, 2015, S255 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Almenara Michelena, C. Ascaso, F.J. Idoate, A. Caramello, C.M. Sánchez, J.I. Berniolles, J. Cristobal, J. Almenara Michelena, C. Ascaso, F.J. Idoate, A. Caramello, C.M. Sánchez, J.I. Berniolles, J. Cristobal, J. |
|---|---|
| author |
Almenara Michelena, C. Ascaso, F.J. Idoate, A. Caramello, C.M. Sánchez, J.I. Berniolles, J. Cristobal, J. |
| spellingShingle |
Almenara Michelena, C. Ascaso, F.J. Idoate, A. Caramello, C.M. Sánchez, J.I. Berniolles, J. Cristobal, J. Acta Ophthalmologica Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion Ophthalmology General Medicine |
| author_sort |
almenara michelena, c. |
| spelling |
Almenara Michelena, C. Ascaso, F.J. Idoate, A. Caramello, C.M. Sánchez, J.I. Berniolles, J. Cristobal, J. 1755-375X 1755-3768 Wiley Ophthalmology General Medicine http://dx.doi.org/10.1111/j.1755-3768.2015.0712 <jats:sec><jats:title>Purpose</jats:title><jats:p>To analyse the evolution of macular hyperreflective points (<jats:styled-content style="fixed-case">HRP</jats:styled-content>) detected by spectral‐domain optical coherence tomography (<jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content>) in eyes with macular edema secondary to retinal vein occlusion (<jats:styled-content style="fixed-case">RVO</jats:styled-content>), following treatment with intravitreal dexamethasone implant (Ozurdex<jats:sup>®</jats:sup>).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective observational study of 45 consecutive cases of <jats:styled-content style="fixed-case">RVO</jats:styled-content>‐associated macular edema: 13 central <jats:styled-content style="fixed-case">RVO</jats:styled-content> and 32 branch <jats:styled-content style="fixed-case">RVO</jats:styled-content> treated with Ozurdex<jats:sup>®</jats:sup>. The relationship between best corrected visual acuity (<jats:styled-content style="fixed-case">BCVA</jats:styled-content>), central macular thickness (<jats:styled-content style="fixed-case">CMT</jats:styled-content>) and the presence of <jats:styled-content style="fixed-case">HRD</jats:styled-content> in <jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content> before treatment and two months post‐injection was determined.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p><jats:styled-content style="fixed-case">CMT</jats:styled-content> decreased significantly following treatment (527.7 μm vs 308.3 μm, p < 0.001). Although there was a visual acuity improvement in 18 of the 45 eyes (40%), the mean <jats:styled-content style="fixed-case">BCVA</jats:styled-content> difference was not statistically significant (p = 0.373). Numerous <jats:styled-content style="fixed-case">HRP</jats:styled-content> were detected in 24 patients (53.3%), disappearing in 10 of them (41.7%) after corticosteroid intravitreal therapy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Disappearance of <jats:styled-content style="fixed-case">HRP</jats:styled-content> after an intravitreal dexamethasone impant would support the hypothesis that <jats:styled-content style="fixed-case">HRP</jats:styled-content> could represent some inflammatory cells.</jats:p></jats:sec> Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion Acta Ophthalmologica |
| doi_str_mv |
10.1111/j.1755-3768.2015.0712 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE3NTUtMzc2OC4yMDE1LjA3MTI |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE3NTUtMzc2OC4yMDE1LjA3MTI |
| institution |
DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 |
| imprint |
Wiley, 2015 |
| imprint_str_mv |
Wiley, 2015 |
| issn |
1755-375X 1755-3768 |
| issn_str_mv |
1755-375X 1755-3768 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
almenaramichelena2015evolutionofhiperreflectivepointsafterintravitrealdexamethasoneimplantinjectioninpatientswithmacularedemaassociatedwithretinalveinocclusion |
| publishDateSort |
2015 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Acta Ophthalmologica |
| source_id |
49 |
| title |
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_unstemmed |
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_full |
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_fullStr |
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_full_unstemmed |
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_short |
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_sort |
evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| topic |
Ophthalmology General Medicine |
| url |
http://dx.doi.org/10.1111/j.1755-3768.2015.0712 |
| publishDate |
2015 |
| physical |
|
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p>To analyse the evolution of macular hyperreflective points (<jats:styled-content style="fixed-case">HRP</jats:styled-content>) detected by spectral‐domain optical coherence tomography (<jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content>) in eyes with macular edema secondary to retinal vein occlusion (<jats:styled-content style="fixed-case">RVO</jats:styled-content>), following treatment with intravitreal dexamethasone implant (Ozurdex<jats:sup>®</jats:sup>).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective observational study of 45 consecutive cases of <jats:styled-content style="fixed-case">RVO</jats:styled-content>‐associated macular edema: 13 central <jats:styled-content style="fixed-case">RVO</jats:styled-content> and 32 branch <jats:styled-content style="fixed-case">RVO</jats:styled-content> treated with Ozurdex<jats:sup>®</jats:sup>. The relationship between best corrected visual acuity (<jats:styled-content style="fixed-case">BCVA</jats:styled-content>), central macular thickness (<jats:styled-content style="fixed-case">CMT</jats:styled-content>) and the presence of <jats:styled-content style="fixed-case">HRD</jats:styled-content> in <jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content> before treatment and two months post‐injection was determined.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p><jats:styled-content style="fixed-case">CMT</jats:styled-content> decreased significantly following treatment (527.7 μm vs 308.3 μm, p < 0.001). Although there was a visual acuity improvement in 18 of the 45 eyes (40%), the mean <jats:styled-content style="fixed-case">BCVA</jats:styled-content> difference was not statistically significant (p = 0.373). Numerous <jats:styled-content style="fixed-case">HRP</jats:styled-content> were detected in 24 patients (53.3%), disappearing in 10 of them (41.7%) after corticosteroid intravitreal therapy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Disappearance of <jats:styled-content style="fixed-case">HRP</jats:styled-content> after an intravitreal dexamethasone impant would support the hypothesis that <jats:styled-content style="fixed-case">HRP</jats:styled-content> could represent some inflammatory cells.</jats:p></jats:sec> |
| container_issue |
S255 |
| container_start_page |
0 |
| container_title |
Acta Ophthalmologica |
| container_volume |
93 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792333647439724552 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:16:03.43Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Evolution+of+hiperreflective+points+after+intravitreal+dexamethasone+implant+injection+in+patients+with+macular+edema+associated+with+retinal+vein+occlusion&rft.date=2015-10-01&genre=article&issn=1755-3768&volume=93&issue=S255&jtitle=Acta+Ophthalmologica&atitle=Evolution+of+hiperreflective+points+after+intravitreal+dexamethasone+implant+injection+in+patients+with+macular+edema+associated+with+retinal+vein+occlusion&aulast=Cristobal&aufirst=J.&rft_id=info%3Adoi%2F10.1111%2Fj.1755-3768.2015.0712&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792333647439724552 |
| author | Almenara Michelena, C., Ascaso, F.J., Idoate, A., Caramello, C.M., Sánchez, J.I., Berniolles, J., Cristobal, J. |
| author_facet | Almenara Michelena, C., Ascaso, F.J., Idoate, A., Caramello, C.M., Sánchez, J.I., Berniolles, J., Cristobal, J., Almenara Michelena, C., Ascaso, F.J., Idoate, A., Caramello, C.M., Sánchez, J.I., Berniolles, J., Cristobal, J. |
| author_sort | almenara michelena, c. |
| container_issue | S255 |
| container_start_page | 0 |
| container_title | Acta Ophthalmologica |
| container_volume | 93 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p>To analyse the evolution of macular hyperreflective points (<jats:styled-content style="fixed-case">HRP</jats:styled-content>) detected by spectral‐domain optical coherence tomography (<jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content>) in eyes with macular edema secondary to retinal vein occlusion (<jats:styled-content style="fixed-case">RVO</jats:styled-content>), following treatment with intravitreal dexamethasone implant (Ozurdex<jats:sup>®</jats:sup>).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective observational study of 45 consecutive cases of <jats:styled-content style="fixed-case">RVO</jats:styled-content>‐associated macular edema: 13 central <jats:styled-content style="fixed-case">RVO</jats:styled-content> and 32 branch <jats:styled-content style="fixed-case">RVO</jats:styled-content> treated with Ozurdex<jats:sup>®</jats:sup>. The relationship between best corrected visual acuity (<jats:styled-content style="fixed-case">BCVA</jats:styled-content>), central macular thickness (<jats:styled-content style="fixed-case">CMT</jats:styled-content>) and the presence of <jats:styled-content style="fixed-case">HRD</jats:styled-content> in <jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content> before treatment and two months post‐injection was determined.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p><jats:styled-content style="fixed-case">CMT</jats:styled-content> decreased significantly following treatment (527.7 μm vs 308.3 μm, p < 0.001). Although there was a visual acuity improvement in 18 of the 45 eyes (40%), the mean <jats:styled-content style="fixed-case">BCVA</jats:styled-content> difference was not statistically significant (p = 0.373). Numerous <jats:styled-content style="fixed-case">HRP</jats:styled-content> were detected in 24 patients (53.3%), disappearing in 10 of them (41.7%) after corticosteroid intravitreal therapy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Disappearance of <jats:styled-content style="fixed-case">HRP</jats:styled-content> after an intravitreal dexamethasone impant would support the hypothesis that <jats:styled-content style="fixed-case">HRP</jats:styled-content> could represent some inflammatory cells.</jats:p></jats:sec> |
| doi_str_mv | 10.1111/j.1755-3768.2015.0712 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE3NTUtMzc2OC4yMDE1LjA3MTI |
| imprint | Wiley, 2015 |
| imprint_str_mv | Wiley, 2015 |
| institution | DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3 |
| issn | 1755-375X, 1755-3768 |
| issn_str_mv | 1755-375X, 1755-3768 |
| language | English |
| last_indexed | 2024-03-01T14:16:03.43Z |
| match_str | almenaramichelena2015evolutionofhiperreflectivepointsafterintravitrealdexamethasoneimplantinjectioninpatientswithmacularedemaassociatedwithretinalveinocclusion |
| mega_collection | Wiley (CrossRef) |
| physical | |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Acta Ophthalmologica |
| source_id | 49 |
| spelling | Almenara Michelena, C. Ascaso, F.J. Idoate, A. Caramello, C.M. Sánchez, J.I. Berniolles, J. Cristobal, J. 1755-375X 1755-3768 Wiley Ophthalmology General Medicine http://dx.doi.org/10.1111/j.1755-3768.2015.0712 <jats:sec><jats:title>Purpose</jats:title><jats:p>To analyse the evolution of macular hyperreflective points (<jats:styled-content style="fixed-case">HRP</jats:styled-content>) detected by spectral‐domain optical coherence tomography (<jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content>) in eyes with macular edema secondary to retinal vein occlusion (<jats:styled-content style="fixed-case">RVO</jats:styled-content>), following treatment with intravitreal dexamethasone implant (Ozurdex<jats:sup>®</jats:sup>).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective observational study of 45 consecutive cases of <jats:styled-content style="fixed-case">RVO</jats:styled-content>‐associated macular edema: 13 central <jats:styled-content style="fixed-case">RVO</jats:styled-content> and 32 branch <jats:styled-content style="fixed-case">RVO</jats:styled-content> treated with Ozurdex<jats:sup>®</jats:sup>. The relationship between best corrected visual acuity (<jats:styled-content style="fixed-case">BCVA</jats:styled-content>), central macular thickness (<jats:styled-content style="fixed-case">CMT</jats:styled-content>) and the presence of <jats:styled-content style="fixed-case">HRD</jats:styled-content> in <jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content> before treatment and two months post‐injection was determined.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p><jats:styled-content style="fixed-case">CMT</jats:styled-content> decreased significantly following treatment (527.7 μm vs 308.3 μm, p < 0.001). Although there was a visual acuity improvement in 18 of the 45 eyes (40%), the mean <jats:styled-content style="fixed-case">BCVA</jats:styled-content> difference was not statistically significant (p = 0.373). Numerous <jats:styled-content style="fixed-case">HRP</jats:styled-content> were detected in 24 patients (53.3%), disappearing in 10 of them (41.7%) after corticosteroid intravitreal therapy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Disappearance of <jats:styled-content style="fixed-case">HRP</jats:styled-content> after an intravitreal dexamethasone impant would support the hypothesis that <jats:styled-content style="fixed-case">HRP</jats:styled-content> could represent some inflammatory cells.</jats:p></jats:sec> Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion Acta Ophthalmologica |
| spellingShingle | Almenara Michelena, C., Ascaso, F.J., Idoate, A., Caramello, C.M., Sánchez, J.I., Berniolles, J., Cristobal, J., Acta Ophthalmologica, Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion, Ophthalmology, General Medicine |
| title | Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_full | Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_fullStr | Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_full_unstemmed | Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_short | Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_sort | evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| title_unstemmed | Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion |
| topic | Ophthalmology, General Medicine |
| url | http://dx.doi.org/10.1111/j.1755-3768.2015.0712 |